<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Heart failure in patients with diabetes mellitus: Epidemiology, pathophysiology, and management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Heart failure in patients with diabetes mellitus: Epidemiology, pathophysiology, and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Heart failure in patients with diabetes mellitus: Epidemiology, pathophysiology, and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shannon M Dunlay, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard W Nesto, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilson S Colucci, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Heart failure (HF) and diabetes mellitus (DM) are each associated with morbidity and mortality and they often occur together with associated greater risk of adverse outcomes [<a href="#rid1">1</a>]</p><p>The epidemiology, pathophysiology, prognosis, and management of HF in patients with diabetes mellitus will be reviewed here. The prevalence of coronary heart disease among patients with DM and the evaluation and general management of HF are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1542.html" rel="external">"Prevalence of and risk factors for coronary heart disease in patients with diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>There is a well-established association between DM and HF that is partly but not entirely linked to coronary heart disease and hypertension.</p><p class="headingAnchor" id="H3"><span class="h2">DM as risk factor for HF</span><span class="headingEndMark"> — </span>Patients with type 2 or type 1 DM are at increased risk for development of HF.</p><p class="headingAnchor" id="H952138927"><span class="h3">Type 2 diabetes mellitus</span><span class="headingEndMark"> — </span>Observational studies of patients with DM (predominantly type 2) have identified an approximately two to fourfold risk of HF compared to individuals without DM [<a href="#rid1">1</a>], and the risk may be even higher in younger individuals (eg, 11-fold in individuals &lt;45 years old [<a href="#rid2">2</a>]). Patients with insulin-resistant states such as obesity and prediabetes are also at increased risk for development of HF [<a href="#rid3">3-5</a>].</p><p>The risk of HF associated with DM may be slightly higher in women compared with men [<a href="#rid1">1,6</a>]. A meta-analysis of population-based cohort studies published between 1966 and 2018 included data on type 2 DM from 13 studies of 47 cohorts with 11,925,128 individuals with 249,560 incident HF events [<a href="#rid6">6</a>]. Among the seven included studies presenting data on absolute risks of HF, the risk in women ranged from 1.94 to 20.85 per 1000 person-years and the risk in men ranged from 1.70 to 28.46 per 1000 person-years in these cohorts. The adjusted relative risk (RR) for HF in individuals with type 2 DM compared with controls was 1.95 (95% CI 1.70-2.22) in women and 1.74 (95% CI 1.55-1.95) in men; the pooled adjusted women-to-men ratio of RRs (RRR) was 1.09 (95% CI 1.05-1.13).</p><p>While the relative risk of HF in patients with DM compared with patients without DM is higher in younger individuals [<a href="#rid2">2</a>], the frequency of HF is higher in older adults as illustrated by a national sample of Medicare claims from 1994 to 1999 for over 150,000 beneficiaries with DM who were ≥65 years of age [<a href="#rid7">7</a>]. The prevalence of HF was 22.3 percent in 1994, with a subsequent incidence of newly diagnosed HF of 12.6 percent per year.</p><p>Factors associated with HF in adult diabetic patients include [<a href="#rid2">2,7-12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Duration of DM</p><p class="bulletIndent1"><span class="glyph">●</span>Insulin use</p><p class="bulletIndent1"><span class="glyph">●</span>Poor glycemic control</p><p class="bulletIndent1"><span class="glyph">●</span>Greater body mass index (BMI)</p><p class="bulletIndent1"><span class="glyph">●</span>Microalbuminuria</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum creatinine</p><p class="bulletIndent1"><span class="glyph">●</span>Ischemic heart disease</p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral artery disease</p><p></p><p>While studies have shown an association between poor glycemic control and risk of HF, improved glucose control has not been shown to reduce incident HF. A meta-analysis including 27,049 patients with type 2 DM found that more intensive glucose control, compared with less intensive control, did not decrease incident HF or mortality, although major cardiovascular events (primarily myocardial infarction [MI]) were decreased [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H2510083013"><span class="h3">Type 1 diabetes mellitus</span><span class="headingEndMark"> — </span>HF is more prevalent in individuals with type 1 DM compared with controls, and the relative risk is higher among women. A meta-analysis of population-based cohort studies included two studies with 3,284,123 individuals with type 1 DM and 95,129 incident HF events [<a href="#rid6">6</a>]. Absolute rates of HF in these cohorts were 3.01 and 7.16 per 1000 person-years in women and 3.71 and 7.11 per 1000 person-years in men. The adjusted RRs for HF associated with type 1 diabetes were 5.15 (95% CI 3.43-7.74) in women and 3.47 (95% CI 2.57-4.69) in men. The women-to-men RRR was 1.47 (95% CI 1.14-1.90).</p><p>Worse glycemic control and presence of albuminuria are both associated with increased risk of HF [<a href="#rid14">14,15</a>]. As an example, in a study of 20,985 adults with DM, the incidence of HF ranged from 1.42 per 1000 patient-years for HbA1c &lt;6.5 percent to 5.20 per 1000 for ≥10.5 percent [<a href="#rid15">15</a>]. After adjustment for covariates, each 1 percent increase in HbA1c was associated with a 30 percent increased relative risk of HF during follow-up.</p><p>In patients with type 1 DM, there is evidence of decreased cardiovascular events (such as nonfatal MI, stroke, cardiovascular death, angina or coronary revascularization) and mortality with intensive insulin therapy (see  <a class="medical medical_review" href="/z/d/html/1751.html" rel="external">"Glycemic control and vascular complications in type 1 diabetes mellitus"</a>). However, data are lacking on the effect of intensive glucose control on risk of incident HF.</p><p class="headingAnchor" id="H3871161405"><span class="h2">HF as risk factor for DM</span><span class="headingEndMark"> — </span>Not only is there an increased risk of developing HF in patients with DM, there is also a high rate of incident type 2 DM among patients with HF. This risk was illustrated by analysis of data from the <a class="drug drug_general" data-topicid="8670" href="/z/d/drug information/8670.html" rel="external">Candesartan</a> in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program and <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">Eplerenone</a> in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) trial; the incidence of DM was 28 and 21 per 1000 person-years in these studies which is higher than expected for adults of in the general population of similar age (approximately 10 per 1000 person years for adults 45 and older) [<a href="#rid1">1,16,17</a>]. Risk factors for incident DM include longer duration of HF, diuretic therapy, and higher New York Heart Association (NYHA) functional class [<a href="#rid1">1,16,17</a>].</p><p class="headingAnchor" id="H5"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Evidence suggests that DM can cause myocardial dysfunction leading to HF. It has also been postulated that HF contributes to the development of DM.</p><p class="headingAnchor" id="H3167893696"><span class="h2">DM as cause of HF</span><span class="headingEndMark"> — </span>DM triggers processes that promote atherosclerosis and coronary artery disease (CAD); DM also triggers processes that may cause myocardial disease without major epicardial CAD (known as diabetic cardiomyopathy) [<a href="#rid1">1</a>]. The effect of DM on cardiac function is thought to be mediated by associated conditions including hyperglycemia, and for patients with type 2 DM, insulin resistance and hyperinsulinemia.</p><p class="headingAnchor" id="H3704804674"><span class="h3">Coronary artery disease</span><span class="headingEndMark"> — </span>In patients with DM, hyperglycemia, insulin resistance and hyperinsulinemia trigger vascular smooth muscle cell proliferation, inflammation, dyslipidemia and endothelial dysfunction leading to accelerated CAD. CAD is the major cause of myocardial ischemia and infarction which results in myocardial dysfunction. The term "ischemic cardiomyopathy" is commonly used to describe significant myocardial dysfunction with left ventricular ejection fraction (LVEF) ≤40 percent caused by CAD (although the technical definition of "cardiomyopathy" excludes dysfunction caused by CAD). (See  <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies", section on 'Definition and classification'</a>.)</p><p class="headingAnchor" id="H3609443831"><span class="h3">Diabetic cardiomyopathy</span><span class="headingEndMark"> — </span>Diabetic cardiomyopathy has been defined as ventricular systolic or diastolic dysfunction in a patient with DM without other recognized cause (such as CAD or hypertension) [<a href="#rid18">18-20</a>]. There is limited evidence on the prevalence of diabetic cardiomyopathy.</p><p class="bulletIndent1"><span class="glyph">●</span>A study of 2042 residents of Olmsted County aged ≥45 years found a community population prevalence of 1.1 percent [<a href="#rid21">21</a>]. Among individuals with DM, 16.9 percent met criteria for diabetic cardiomyopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a pooled cohort study that included patients with diabetes, the prevalence of LV dysfunction varied from 67 to 12 percent and depended on the criteria used to define the presence of LV dysfunction [<a href="#rid22">22</a>]. Among asymptomatic patients with evidence of LV dysfunction, the five-year incidence of symptomatic HF was 8 to 13 percent in the least to most restrictive groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is some evidence that diabetic cardiomyopathy is uncommon in patients with type 1 diabetes in the era of intensive insulin therapy [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H3470684128"><span class="h4">Functional and structural abnormalities</span><span class="headingEndMark"> — </span>The following cardiac and hemodynamic alterations have been observed in patients with DM [<a href="#rid24">24-27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Higher LV mass, wall thickness, and arterial stiffness and reduced systolic function compared with individuals without DM [<a href="#rid28">28</a>]. These abnormalities were independent of BMI and blood pressure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged pre-ejection period and a shortened ejection time, both of which correlate with reduced resting LV ejection fraction (LVEF) and diminished systolic function [<a href="#rid18">18</a>]. Diabetic patients also have a lower LVEF in response to exercise, suggesting a reduction in cardiac reserve [<a href="#rid29">29,30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diastolic dysfunction [<a href="#rid31">31,32</a>], which may be due in part to increased LV mass [<a href="#rid32">32,33</a>]. For example, an E/e' ratio &gt;15 (a marker of elevated LV diastolic pressure) was observed in 23 percent of 1760 diabetic patients studied in Olmsted County [<a href="#rid32">32</a>]. Greater diastolic dysfunction has been observed in diabetic patients with worse glycemic control and in those who are also hypertensive [<a href="#rid34">34</a>]. In an observational study, HbA1c level correlated with E/e' ratio as well as reduced six-minute walk distance on multivariate analysis [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"</a>.)</p><p></p><p>Pathologic changes in the myocardium have been described in diabetic patients that may account for observed functional changes [<a href="#rid35">35-37</a>]. These include fibrosis, infiltration of the interstitium with periodic acid-Schiff (PAS)-positive material, and alterations in the myocardial capillary basement membrane, including the formation of microaneurysms.</p><p class="headingAnchor" id="H2036999814"><span class="h4">Etiology</span><span class="headingEndMark"> — </span>A variety of derangements associated with DM may contribute to ventricular dysfunction [<a href="#rid19">19,38,39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Insulin resistance and hyperinsulinemia may cause LV hypertrophy and associated diastolic dysfunction. Diastolic dysfunction is highly prevalent in patients with DM [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Advanced glycation end product deposition may increase LV diastolic stiffness and impaired cardiac relaxation directly by cross-linking collagen, or indirectly by enhancing collagen formation or reducing nitric oxide bioavailability [<a href="#rid41">41-43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autonomic neuropathy may play a role in the development of LV dysfunction [<a href="#rid18">18</a>]. Sympathetic stimulation increases LV contraction and also increases LV relaxation rates, the latter perhaps by facilitating calcium uptake by the sarcoplasmic reticulum. Autopsy studies in diabetic patients have found depleted myocardial catecholamine stores which could impair both systolic and diastolic function [<a href="#rid44">44</a>]. These changes may be associated with functional impairment in cardiac sympathetic nerve fibers [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The capacity of the vascular bed to meet metabolic demands may be impaired by abnormal epicardial vessel tone and microvascular dysfunction [<a href="#rid27">27,46</a>]. Diabetics have impaired endothelium-dependent relaxation [<a href="#rid47">47</a>], a defect that may be related to inactivation of nitric oxide by advanced glycation end products and by increased generation of free radicals [<a href="#rid48">48</a>]. The abnormal vasodilator response in diabetes extends to the coronary microcirculation [<a href="#rid49">49</a>]. Microcirculatory dysfunction in diabetics may be due in part to downregulation of the expression of vascular endothelial growth factor (VEGF).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased insulin availability or responsiveness can impair energy-independent transport of glucose across the cell membrane. Since ischemic myocardium depends upon anaerobic metabolism of glucose, increased glucose uptake and metabolism are necessary for maintenance of myocardial function [<a href="#rid50">50,51</a>]. Diminished insulin activity limits glucose availability, resulting in a shift toward fatty acid metabolism. These changes increase myocardial oxygen utilization and can reduce the compensatory capacity of noninfarcted myocardium [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other factors that may contribute include myocardial accumulation of lipid and other toxic products of fatty acid metabolism [<a href="#rid53">53-55</a>], impaired calcium handling [<a href="#rid19">19,56,57</a>], upregulation of the renin-angiotensin system [<a href="#rid19">19,58</a>], increased reactive oxygen species [<a href="#rid19">19,59</a>], and mitochondrial defects [<a href="#rid19">19,38</a>].</p><p></p><p class="headingAnchor" id="H3509851008"><span class="h2">HF as cause of DM</span><span class="headingEndMark"> — </span>While clinical and laboratory evidence support the above proposed mechanisms by which diabetes and insulin resistance may cause HF, a reciprocal causal relation has been postulated in which HF promotes insulin resistance [<a href="#rid39">39</a>]. Neurohumoral activation in HF causes increased free fatty acid metabolism, which may cause systemic and myocardial insulin resistance. These metabolic alterations may impair myocardial energetics so that a vicious cycle is produced of HF leading to altered metabolism leading to HF.</p><p class="headingAnchor" id="H7"><span class="h1">PROGNOSIS IN PATIENTS WITH HF AND DM</span><span class="headingEndMark"> — </span>Among patients with HF, those with DM have worse outcomes as demonstrated by studies of community-based HF cohorts as well as data from randomized trials in patients with HF with reduced ejection fraction (HFrEF; LVEF ≤40 percent) or HF with preserved ejection fraction (HFpEF) [<a href="#rid1">1,60-66</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A study from the CHARM program on outcomes in patients with HF found that concurrent DM was associated with greater increased risk of cardiovascular death or HF hospitalization in patients with LVEF &gt;40 percent (adjusted hazard ratio [HR] 2.0, 95% CI 1.70-2.36) than in patients with LVEF ≤40 percent (adjusted HR 1.60, 95% CI 1.44-1.77) [<a href="#rid65">65</a>]. For all-cause mortality, the risk conferred by DM was similar in the two groups (adjusted HR 1.84, 95% CI 1.51–2.26 and adjusted HR 1.55, 95% CI 1.38–1.74).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the PARADIGM-HF trial enrolling patients with HFrEF, there was increased risk of the primary composite outcome of HF hospitalization or cardiovascular mortality in patients with previously undiagnosed DM (HR 1.39, 95% CI 1.17-1.64) or known DM (HR 1.64, 95% CI 1.43-1.87) compared with patients with hemoglobin A1c (HbA1c) &lt;6.0 percent [<a href="#rid63">63</a>]. Patients with pre-diabetes mellitus were also at higher risk (HR 1.27, 95% CI 1.10-1.47) compared with those with HbA1c &lt;6.0 percent.</p><p></p><p>Among patients with diabetes, those who develop HF have markedly poorer survival than in those who do not.</p><p class="bulletIndent1"><span class="glyph">●</span>In a national sample of Medicare claims, the mortality rates were 32.7 and 3.7 percent per year, respectively (HR 10.6) [<a href="#rid7">7</a>]. This risk was only slightly attenuated by adjustment for age, sex, and race (HR 9.5). The five-year survival rate for diabetics with HF was 12.5 percent.</p><p></p><p class="headingAnchor" id="H13"><span class="h1">MANAGEMENT OF HF IN DM</span><span class="headingEndMark"> — </span>Management of HF in patients with DM is largely the same as treatment of HF in patients without DM. Multidisciplinary team-based care may be helpful although specific data on programs for patients with HF and DM are limited [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H14"><span class="h2">General management</span><span class="headingEndMark"> — </span>General management of patients with HF and DM includes lifestyle modification, support of self-care, and palliative care. In addition, management of HFrEF and HFpEF includes exercise training. Data from the HF-ACTION trial showed that patients with HFrEF with concurrent DM had lower baseline functional capacity but significant improvements in peak VO<sub>2</sub> and six-minute walk distance [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/3472.html" rel="external">"Cardiac rehabilitation in patients with heart failure"</a>.)</p><p class="headingAnchor" id="H316074846"><span class="h2">Pharmacologic therapy</span></p><p class="headingAnchor" id="H3838086930"><span class="h3">For HFrEF</span><span class="headingEndMark"> — </span>Pharmacologic therapy for HFrEF in adults with DM is generally the same as for adults with HFrEF; the efficacy of the medical regimen is similar in these two groups. Data supporting this approach for HFrEF are available for angiotensin system blockers (angiotensin converting enzyme [ACE] inhibitor, angiotensin II receptor blocker [ARB], or angiotensin receptor-neprilysin inhibitor [ARNI]), beta blockers, mineralocorticoid receptor antagonists [MRAs], and sodium-glucose co-transporter 2 (SGLT2) inhibitors [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiotensin system blockers and </strong><strong>sacubitril-valsartan</strong> – Angiotensin system blockers have favorable effects on the development of DM and glycemic control in patients with HFrEF [<a href="#rid1">1</a>] and have similar efficacy in patients with and without DM:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a meta-analysis of ACE inhibitor trials in HFrEF that included 2398 patients with diabetes and 10,188 patients without diabetes, the survival benefit with ACE inhibitor therapy was similar for those with diabetes as for those without (relative risk [RR] 0.84 and 0.85, respectively) [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In ARB trials in patients with HF (some but not all limited to HFrEF), similar benefits on composite outcomes were observed in patients with and without DM [<a href="#rid1">1</a>]. As an example, in the CHARM program which enrolled patients with HFrEF and HF with LVEF &gt;40 percent, the beneficial effect of <a class="drug drug_general" data-topicid="8670" href="/z/d/drug information/8670.html" rel="external">candesartan</a> on cardiovascular morbidity and mortality was similar in patients with and without DM [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In PARADIGM-HF, the benefit of the ARNI <a class="drug drug_general" data-topicid="102505" href="/z/d/drug information/102505.html" rel="external">sacubitril-valsartan</a> compared with <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">enalapril</a> in patients with HFrEF was consistent across the range of HbA1c [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockers</strong> – Beta blockers were found to have generally similar mortality benefits in patients with HFrEF with and without DM (eg, RR of mortality from HF 0.77, 95% CI 0.61-0.96 in diabetics and RR 0.65, 95% CI 0.57-0.74 in nondiabetics [<a href="#rid68">68</a>]) in meta-analyses [<a href="#rid1">1</a>]. However, one meta-analysis found a greater benefit in individuals without DM (RR of mortality 0.84, 95% CI 0.73-0.96 in diabetics and RR 0.72, 95% CI 0.65-0.79 in nondiabetics) [<a href="#rid69">69</a>]. Each of the three beta blockers with established efficacy in reduce mortality in patients with HFrEF (<a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">carvedilol</a>, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> succinate, and <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">bisoprolol</a>), also reduce mortality in the subgroup of patients with DM and HFrEF with generally similar degrees of risk reduction [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">Carvedilol</a> may have favorable effects on glycemic control not identified with <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">bisoprolol</a> or <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> tartrate [<a href="#rid1">1,70-74</a>]. Therefore, carvedilol may be preferred in patients with HFrEF with poorly controlled DM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mineralocorticoid receptor antagonists</strong> – In the EMPHASIS-HF trial in patients with HFrEF, the beneficial effect of <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a> compared with placebo was similar in patients with DM (hazard ratio [HR] 0.54, 95% CI 0.42-0.70) and without DM (HR 0.72, 95% CI 0.58-0.88) [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1">For patients who are candidates for MRA therapy, <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> may have less effect on blood glucose levels than <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a>, though the differences may not be clinically significant. A systematic review of 18 randomized trials found that spironolactone slightly increased hemoglobin A1c by an average of 0.16 percent (95% CI 0.02-0.30) [<a href="#rid76">76</a>]. In a small randomized trial in patients with HFrEF, the hemoglobin A1c was significantly increased in patients treated with spironolactone 25 mg daily (from 5.61 percent to 5.8 percent) but not in those treated with eplerenone 50 mg daily [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sodium-glucose co-transporter 2 inhibitors</strong> – The SGLT2 inhibitor <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">dapagliflozin</a> had similarly beneficial effects on the primary composite outcome (hospitalization for HF, an urgent visit resulting in intravenous therapy for HF, or death from cardiovascular causes) in patients with type 2 DM (HR 0.75, 95% CI 0.63-0.90) and without type 2 DM (HR 0.73, 95% CI 0.60-0.88) in the DAPA-HF trial [<a href="#rid78">78</a>]. In addition, the effect of <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">empagliflozin</a> on the combined endpoint of cardiovascular death or HF hospitalization was similar in patients with type 2 DM (HR 0.72, 95% CI 0.60-0.87) and without type 2 DM (HR 0.78, 95% CI 0.64-0.97) [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1">Use of SGLT2 inhibitors in patients with HFrEF (with or without type 2 DM) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Primary components of therapy'</a> and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Sodium-glucose co-transporter 2 inhibitors'</a>.)</p><p></p><p class="bulletIndent1">In patients with HF and diabetes, additional agents for the treatment of HF may be indicated. Subgroup analyses of large trials that evaluated the efficacy of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> [<a href="#rid80">80</a>], <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a> [<a href="#rid81">81</a>], and <a class="drug drug_general" data-topicid="130565" href="/z/d/drug information/130565.html" rel="external">vericiguat</a> [<a href="#rid82">82</a>] found similar efficacy between patients with and without diabetes. A complete discussion of these agents can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction"</a>.)</p><p></p><p class="headingAnchor" id="H176927748"><span class="h3">For HFpEF</span><span class="headingEndMark"> — </span>Pharmacologic therapy of HFpEF in adults with DM is the same as that for other adults and includes appropriate use of diuretics, an SGLT2 inhibitor, MRA, and <a class="drug drug_general" data-topicid="102505" href="/z/d/drug information/102505.html" rel="external">sacubitril-valsartan</a>. The approach to use of these agents in patients with HFpEF with and without DM is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction", section on 'Pharmacotherapy'</a>.)</p><p class="headingAnchor" id="H2923054847"><span class="h2">Device therapy</span><span class="headingEndMark"> — </span>Standard indications for implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT) apply to patients with DM and HF. Studies have found similar improvements in outcomes from ICD (for primary prevention of sudden cardiac arrest) and/or CRT therapy in patients with and without DM [<a href="#rid1">1</a>]. One exception is the SCD-HeFT trial in patients with HFrEF with LVEF ≤35 percent; the reduction in death with ICD in patients with DM (HR 0.95, 97.5% CI 0.68-1.33) was nominally less but overlapped that in patients without DM (HR 0.67, 97.5% CI 0.50-0.90). Presence of DM is a risk factor for worse survival in patients receiving ICDs for secondary prevention of sudden cardiac arrest [<a href="#rid83">83</a>] but data are lacking on the impact of DM on the efficacy of ICD therapy for secondary prevention. (See  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a> and  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a> and  <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">"Cardiac resynchronization therapy in heart failure: Indications and choice of system"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Advanced therapies</span><span class="headingEndMark"> — </span>Heart transplantation is an option for selected patients with DM and advanced HF. DM in common among patients undergoing heart transplantation (eg, 18 percent in one series) [<a href="#rid84">84</a>]. DM with evidence of significant end-organ damage (eg, neuropathy or nephropathy, but not nonproliferative retinopathy) or persistent poor glycemic control (glycosylated hemoglobin [HbA1c] &gt;7.5 percent or 58 mmol/mol) despite optimal effort is a relative contraindication to heart transplantation [<a href="#rid85">85</a>]. However, carefully selected patients with DM without significant renal dysfunction can undergo successful cardiac transplantation with similar morbidity and mortality as patients without DM. For selected patients with DM and renal dysfunction, combined heart and kidney transplantation is an option. (See  <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications"</a>.)</p><p>DM with severe end-organ damage is a relative contraindication to durable mechanical circulatory support. Among patients with advanced HF and DM who undergo LVAD placement, glycemic control often improves [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/87834.html" rel="external">"Management of long-term mechanical circulatory support devices"</a> and  <a class="medical medical_review" href="/z/d/html/3459.html" rel="external">"Treatment of advanced heart failure with a durable mechanical circulatory support device"</a>.)</p><p class="headingAnchor" id="H3128797209"><span class="h1">MANAGEMENT OF DM IN HF</span><span class="headingEndMark"> — </span>The initial management of blood glucose as well as the general medical care in adults with type 2 or type 1 diabetes mellitus and HF is similar to that for other adults. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Initial pharmacologic therapy'</a> and  <a class="medical medical_review" href="/z/d/html/1796.html" rel="external">"Management of blood glucose in adults with type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus"</a>.)</p><p>For patients with type 2 diabetes and HF, who do not tolerate or have suboptimal glycemic control with initial therapy, the choice of alternative or additional glucose-lowering medication is guided by patient comorbidities, and in particular, the presence of clinical cardiovascular disease, including HF. Diabetes medications with demonstrated cardiovascular benefit are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Initial pharmacologic therapy'</a> and  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Our approach'</a>.)</p><p>The use of a sodium-glucose co-transporter 2 (SGLT2) inhibitor to treat patients with HF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction", section on 'Preferred therapies for symptomatic patients'</a>.)</p><p class="headingAnchor" id="H1955199581"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104442.html" rel="external">"Society guideline links: Diabetes mellitus in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a>.)</p><p class="headingAnchor" id="H3042978"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – There is a well-established association between diabetes mellitus (DM) and heart failure (HF) that is partly but not entirely linked to coronary heart disease and hypertension. Patients with type 1 or type 2 DM are at increased risk for development of HF. However, a causal relationship between improved glucose control and reduced HF has not been established. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Evidence suggests that DM can cause myocardial dysfunction leading to HF. DM triggers processes that promote atherosclerosis and coronary artery disease (CAD); DM also triggers processes that may cause myocardial disease without major epicardial CAD (known as diabetic cardiomyopathy) [<a href="#rid1">1</a>]. The effect of DM on cardiac function is thought to be mediated by associated conditions including hyperglycemia, and for patients with type 2 DM, insulin resistance and hyperinsulinemia. (See <a class="local">'DM as cause of HF'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis in patients with HF and DM</strong> – Among patients with HF, those with DM have worse outcomes as demonstrated by studies of community-based HF cohorts as well as data from randomized trials in patients with HF with reduced ejection fraction (HFrEF; left ventricular ejection fraction [LVEF] ≤40 percent) or HF with preserved ejection fraction (HFpEF). (See <a class="local">'Prognosis in patients with HF and DM'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of HF in patients with DM</strong> – Management of HF in patients with DM is largely the same as treatment of HF generally in patients without DM. Multidisciplinary team-based care may be helpful although specific data on programs for patients with HF and DM are limited. (See <a class="local">'Management of HF in DM'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General management</strong> – General management includes lifestyle modification, support of self-care, and exercise training. (See <a class="local">'General management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Therapy for HFrEF</strong> – Pharmacologic therapy for HFrEF in adults with DM is generally the same as for adults with HFrEF given evidence of similar efficacy of for nearly all agents in patients with or without DM. (See <a class="local">'For HFrEF'</a> above and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Therapy for HFpEF</strong> – Pharmacologic therapy for HFpEF in adults with DM is the same as for other adults with HFpEF. (See <a class="local">'For HFpEF'</a> above and  <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Device therapy</strong> – Standard indications for implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT) apply to patients who have HF and DM. (See <a class="local">'Device therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Advanced therapies</strong> – Heart transplantation and durable mechanical circulatory support are options for selected patients with advanced HF and DM without significant end-organ damage. (See <a class="local">'Advanced therapies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 2019; 140:e294.</a></li><li><a class="nounderline abstract_t">Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27:1879.</a></li><li><a class="nounderline abstract_t">Thrainsdottir IS, Aspelund T, Thorgeirsson G, et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 2005; 28:612.</a></li><li><a class="nounderline abstract_t">Bahrami H, Bluemke DA, Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008; 51:1775.</a></li><li><a class="nounderline abstract_t">Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. J Am Coll Cardiol 2018; 71:339.</a></li><li><a class="nounderline abstract_t">Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia 2019; 62:1550.</a></li><li><a class="nounderline abstract_t">Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27:699.</a></li><li><a class="nounderline abstract_t">Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103:2668.</a></li><li><a class="nounderline abstract_t">Barzilay JI, Kronmal RA, Gottdiener JS, et al. The association of fasting glucose levels with congestive heart failure in diabetic adults &gt; or =65 years: the Cardiovascular Health Study. J Am Coll Cardiol 2004; 43:2236.</a></li><li><a class="nounderline abstract_t">Carr AA, Kowey PR, Devereux RB, et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005; 96:1530.</a></li><li><a class="nounderline abstract_t">Halon DA, Merdler A, Flugelman MY, et al. Late-onset heart failure as a mechanism for adverse long-term outcome in diabetic patients undergoing revascularization (a 13-year report from the Lady Davis Carmel Medical Center registry). Am J Cardiol 2000; 85:1420.</a></li><li><a class="nounderline abstract_t">Held C, Gerstein HC, Yusuf S, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007; 115:1371.</a></li><li><a class="nounderline abstract_t">Control Group, Turnbull FM, Abraira C, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52:2288.</a></li><li><a class="nounderline abstract_t">Rosengren A, Vestberg D, Svensson AM, et al. Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes Endocrinol 2015; 3:876.</a></li><li><a class="nounderline abstract_t">Lind M, Bounias I, Olsson M, et al. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 2011; 378:140.</a></li><li><a class="nounderline abstract_t">Preiss D, Zetterstrand S, McMurray JJ, et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care 2009; 32:915.</a></li><li><a class="nounderline abstract_t">Preiss D, van Veldhuisen DJ, Sattar N, et al. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2012; 14:909.</a></li><li><a class="nounderline abstract_t">Zarich SW, Nesto RW. Diabetic cardiomyopathy. Am Heart J 1989; 118:1000.</a></li><li><a class="nounderline abstract_t">Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115:3213.</a></li><li><a class="nounderline abstract_t">Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30:595.</a></li><li><a class="nounderline abstract_t">Dandamudi S, Slusser J, Mahoney DW, et al. The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J Card Fail 2014; 20:304.</a></li><li><a class="nounderline abstract_t">Segar MW, Khan MS, Patel KV, et al. Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. J Am Coll Cardiol 2021; 78:1587.</a></li><li><a class="nounderline abstract_t">Konduracka E, Gackowski A, Rostoff P, et al. Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J 2007; 28:2465.</a></li><li><a class="nounderline abstract_t">Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989; 14:49.</a></li><li><a class="nounderline abstract_t">Vered A, Battler A, Segal P, et al. Exercise-induced left ventricular dysfunction in young men with asymptomatic diabetes mellitus (diabetic cardiomyopathy). Am J Cardiol 1984; 54:633.</a></li><li><a class="nounderline abstract_t">Arvan S, Singal K, Knapp R, Vagnucci A. Subclinical left ventricular abnormalities in young diabetics. Chest 1988; 93:1031.</a></li><li><a class="nounderline abstract_t">Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol 2006; 48:1548.</a></li><li><a class="nounderline abstract_t">Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000; 101:2271.</a></li><li><a class="nounderline abstract_t">Mildenberger RR, Bar-Shlomo B, Druck MN, et al. Clinically unrecognized ventricular dysfunction in young diabetic patients. J Am Coll Cardiol 1984; 4:234.</a></li><li><a class="nounderline abstract_t">Mustonen JN, Uusitupa MI, Laakso M, et al. Left ventricular systolic function in middle-aged patients with diabetes mellitus. Am J Cardiol 1994; 73:1202.</a></li><li><a class="nounderline abstract_t">Stahrenberg R, Edelmann F, Mende M, et al. Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia 2010; 53:1331.</a></li><li><a class="nounderline abstract_t">From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 2010; 55:300.</a></li><li><a class="nounderline abstract_t">Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991; 68:85.</a></li><li><a class="nounderline abstract_t">Liu JE, Palmieri V, Roman MJ, et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 2001; 37:1943.</a></li><li><a class="nounderline abstract_t">Fischer VW, Barner HB, Leskiw ML. Capillary basal laminar thichness in diabetic human myocardium. Diabetes 1979; 28:713.</a></li><li><a class="nounderline abstract_t">Factor SM, Okun EM, Minase T. Capillary microaneurysms in the human diabetic heart. N Engl J Med 1980; 302:384.</a></li><li><a class="nounderline abstract_t">van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990; 82:848.</a></li><li><a class="nounderline abstract_t">An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006; 291:H1489.</a></li><li><a class="nounderline abstract_t">Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007; 116:434.</a></li><li><a class="nounderline abstract_t">Fang ZY, Yuda S, Anderson V, et al. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 2003; 41:611.</a></li><li><a class="nounderline abstract_t">van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008; 117:43.</a></li><li><a class="nounderline abstract_t">Heymes C, Vanderheyden M, Bronzwaer JG, et al. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 1999; 99:3009.</a></li><li><a class="nounderline abstract_t">Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 47:693.</a></li><li><a class="nounderline abstract_t">Neubauer B, Christensen NJ. Norepinephrine, epinephrine, and dopamine contents of the cardiovascular system in long-term diabetics. Diabetes 1976; 25:6.</a></li><li><a class="nounderline abstract_t">Scognamiglio R, Avogaro A, Casara D, et al. Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998; 31:404.</a></li><li><a class="nounderline abstract_t">Rossen JD. Abnormal microvascular function in diabetes: relationship to diabetic cardiomyopathy. Coron Artery Dis 1996; 7:133.</a></li><li><a class="nounderline abstract_t">Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88:2510.</a></li><li><a class="nounderline abstract_t">Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87:432.</a></li><li><a class="nounderline abstract_t">Sebbag L, Forrat R, Canet E, et al. Effect of experimental non-insulin requiring diabetes on myocardial microcirculation during ischaemia in dogs. Eur J Clin Invest 1994; 24:686.</a></li><li><a class="nounderline abstract_t">Wheeler TJ. Translocation of glucose transporters in response to anoxia in heart. J Biol Chem 1988; 263:19447.</a></li><li><a class="nounderline abstract_t">Sun D, Nguyen N, DeGrado TR, et al. Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane of cardiac myocytes. Circulation 1994; 89:793.</a></li><li><a class="nounderline abstract_t">Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 1995; 27:169.</a></li><li><a class="nounderline abstract_t">McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007; 116:1170.</a></li><li><a class="nounderline abstract_t">Ruberg FL. Myocardial lipid accumulation in the diabetic heart. Circulation 2007; 116:1110.</a></li><li><a class="nounderline abstract_t">Rijzewijk LJ, van der Meer RW, Smit JW, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008; 52:1793.</a></li><li><a class="nounderline abstract_t">Cesario DA, Brar R, Shivkumar K. Alterations in ion channel physiology in diabetic cardiomyopathy. Endocrinol Metab Clin North Am 2006; 35:601.</a></li><li><a class="nounderline abstract_t">Jweied EE, McKinney RD, Walker LA, et al. Depressed cardiac myofilament function in human diabetes mellitus. Am J Physiol Heart Circ Physiol 2005; 289:H2478.</a></li><li><a class="nounderline abstract_t">Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87:1123.</a></li><li><a class="nounderline abstract_t">Cai L, Wang Y, Zhou G, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 48:1688.</a></li><li><a class="nounderline abstract_t">Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996; 77:1017.</a></li><li><a class="nounderline abstract_t">Dries DL, Sweitzer NK, Drazner MH, et al. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001; 38:421.</a></li><li><a class="nounderline abstract_t">Gustafsson I, Brendorp B, Seibaek M, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 2004; 43:771.</a></li><li><a class="nounderline abstract_t">Kristensen SL, Preiss D, Jhund PS, et al. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail 2016; 9.</a></li><li><a class="nounderline abstract_t">Allen LA, Magid DJ, Gurwitz JH, et al. Risk factors for adverse outcomes by left ventricular ejection fraction in a contemporary heart failure population. Circ Heart Fail 2013; 6:635.</a></li><li><a class="nounderline abstract_t">MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29:1377.</a></li><li><a class="nounderline abstract_t">Kristensen SL, Mogensen UM, Jhund PS, et al. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation 2017; 135:724.</a></li><li><a class="nounderline abstract_t">Banks AZ, Mentz RJ, Stebbins A, et al. Response to Exercise Training and Outcomes in Patients With Heart Failure and Diabetes Mellitus: Insights From the HF-ACTION Trial. J Card Fail 2016; 22:485.</a></li><li><a class="nounderline abstract_t">Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529.</a></li><li><a class="nounderline abstract_t">Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003; 146:848.</a></li><li><a class="nounderline abstract_t">Torp-Pedersen C, Metra M, Charlesworth A, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 2007; 93:968.</a></li><li><a class="nounderline abstract_t">Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227.</a></li><li><a class="nounderline abstract_t">Ferrua S, Bobbio M, Catalano E, et al. Does carvedilol impair insulin sensitivity in heart failure patients without diabetes? J Card Fail 2005; 11:590.</a></li><li><a class="nounderline abstract_t">Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin 2010; 26:615.</a></li><li><a class="nounderline abstract_t">Wai B, Kearney LG, Hare DL, et al. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol 2012; 11:14.</a></li><li><a class="nounderline abstract_t">Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364:11.</a></li><li><a class="nounderline abstract_t">Zhao JV, Xu L, Lin SL, Schooling CM. Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials. J Am Soc Hypertens 2016; 10:671.</a></li><li><a class="nounderline abstract_t">Yamaji M, Tsutamoto T, Kawahara C, et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure. Am Heart J 2010; 160:915.</a></li><li><a class="nounderline abstract_t">McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381:1995.</a></li><li><a class="nounderline abstract_t">Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383:1413.</a></li><li><a class="nounderline abstract_t">Abdul-Rahim AH, MacIsaac RL, Jhund PS, et al. Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. Int J Cardiol 2016; 209:310.</a></li><li><a class="nounderline abstract_t">Komajda M, Tavazzi L, Francq BG, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail 2015; 17:1294.</a></li><li><a class="nounderline abstract_t">Teerlink JR, Diaz R, Felker GM, et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med 2021; 384:105.</a></li><li><a class="nounderline abstract_t">Oseroff O, Retyk E, Bochoeyer A. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol 2004; 19:26.</a></li><li><a class="nounderline abstract_t">Russo MJ, Chen JM, Hong KN, et al. Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus: an analysis of the United Network of Organ Sharing database. Circulation 2006; 114:2280.</a></li><li><a class="nounderline abstract_t">Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant 2016; 35:1.</a></li></ol></div><div id="topicVersionRevision">Topic 3458 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31167558" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277411" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The incidence of congestive heart failure in type 2 diabetes: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15735197" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The association between glucose abnormalities and heart failure in the population-based Reykjavik study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18452784" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29348027" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31317230" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14988288" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Heart failure prevalence, incidence, and mortality in the elderly with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11390335" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Glycemic control and heart failure among adult patients with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15193686" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The association of fasting glucose levels with congestive heart failure in diabetic adults&gt;or =65 years: the Cardiovascular Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310435" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10856386" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Late-onset heart failure as a mechanism for adverse long-term outcome in diabetic patients undergoing revascularization (a 13-year report from the Lady Davis Carmel Medical Center registry).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17339550" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19655124" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intensive glucose control and macrovascular outcomes in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26388415" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21705065" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19196892" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22611047" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2683698" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diabetic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592090" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Diabetic cardiomyopathy revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4263660" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : New type of cardiomyopathy associated with diabetic glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24576788" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34649696" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17766928" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2661630" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6475785" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Exercise-induced left ventricular dysfunction in young men with asymptomatic diabetes mellitus (diabetic cardiomyopathy).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3359822" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Subclinical left ventricular abnormalities in young diabetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17045886" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10811594" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Impact of diabetes on cardiac structure and function: the strong heart study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6736464" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinically unrecognized ventricular dysfunction in young diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8203339" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Left ventricular systolic function in middle-aged patients with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20386878" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Association of glucose metabolism with diastolic function along the diabetic continuum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20117433" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2058564" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11401136" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/446928" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Capillary basal laminar thichness in diabetic human myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7351930" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Capillary microaneurysms in the human diabetic heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2394006" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16751293" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Role of changes in cardiac metabolism in development of diabetic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646594" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Metabolic mechanisms in heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12598073" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Echocardiographic detection of early diabetic myocardial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071071" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10368118" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16487830" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1245267" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Norepinephrine, epinephrine, and dopamine contents of the cardiovascular system in long-term diabetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9462586" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8813444" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Abnormal microvascular function in diabetes: relationship to diabetic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8080489" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1991829" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7851469" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of experimental non-insulin requiring diabetes on myocardial microcirculation during ischaemia in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3058699" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Translocation of glucose transporters in response to anoxia in heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8313568" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane of cardiac myocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7760340" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Myocardial substrate metabolism: implications for diabetic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698735" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17768302" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Myocardial lipid accumulation in the diabetic heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19022158" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16959588" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Alterations in ion channel physiology in diabetic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16085678" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Depressed cardiac myofilament function in human diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11110769" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Myocardial cell death in human diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17045908" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644628" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11499733" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14998615" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26754626" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23709659" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Risk factors for adverse outcomes by left ventricular ejection fraction in a contemporary heart failure population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413309" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28052977" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26687984" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Response to Exercise Training and Outcomes in Patients With Heart Failure and Diabetes Mellitus: Insights From the HF-ACTION Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742294" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14597934" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17237130" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15536109" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16230261" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Does carvedilol impair insulin sensitivity in heart failure patients without diabetes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20067434" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effects of beta-blockers on glucose and lipid metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22330091" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21073363" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Eplerenone in patients with systolic heart failure and mild symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27372428" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21095280" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31535829" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865377" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26913372" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26377342" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33185990" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14688631" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088463" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus: an analysis of the United Network of Organ Sharing database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26776864" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
